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Abstract: As the numbers of completed outcomes based clinical trials evaluating the use of statin
drugs for the management of cardiovascular risk continue to increase, it is clear that the numbers
of patients that may benefit from these drugs continues to grow. The recently published studies are
reviewed in this summary. The distinction is made between patients requiring either primary or
secondary cardiovascular preventive management. The review identifies the increasing numbers
of patients who may benefit from the use of statins as primary preventive management, and the
changing concepts of the utilization of statin drugs for secondary preventive management, including
the more aggressive titration of the drugs to provide incremental improvement in patient outcomes.
Available data on the use of statins in the elderly patient are reviewed, and observations are made
regarding the intrinsic properties and adverse effects of the drugs.
Keywords: cardiovascular risk, statins, elderly patient.
The management of cholesterol levels in individuals with or without documented
coronary artery disease continues to be modified as more outcomes based research
directed at such individuals is published (Nixon 2004). These trials and studies expand
the profile of the individual or the patient that may potentially benefit from the use of
a statin drug as primary and secondary preventive care in the reduction of their
cardiovascular risk and the consequent improvement in their prognosis.
General principles of cardiovascular risk
management
The management of cholesterol must be placed in the context of the importance of
managing and modifying all cardiovascular risk factors, including obesity and diet,
lack of exercise, and cigarette smoking, risk factors exclusively under the control of
the individual patient. Life style modification, diet, and exercise are essential
components of the management of cardiovascular disease, irrespective of age or gender,
and thus must be emphasized during discussions of patient management. Well-balanced
and prolonged dietary programs, regularly maintained exercise programs and cessation
of cigarette smoking are all critical components of the patient’s ongoing care. These
principles have been reinforced in the recently published extension to the National
Cholesterol Education Program guidelines on detection, evaluation and treatment of
high blood cholesterol in adults (NCEP Expert Panel 2001; Grundy et al 2004).
Preventive management utilizing statin therapy
Reduction of cardiovascular risk of death and/or cardiovascular events in any given
patient may be divided into primary and secondary prevention (Knopp 1999). Primary
prevention incorporates people or patients without a diagnosis of coronary artery disease
and/or who have not suffered an acute cardiovascular event. Secondary prevention
involves patients who have a diagnosis of coronary disease (confirmed by the
documentation of a prior acute cardiac event, coronary disease identified during cardiac
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catheterization, or a positive stress or stress imaging study)
or who have recently suffered an acute cardiac event or acute
coronary syndrome. The recently published outcomes based
research trials using statins as treatment for the reduction of
cardiovascular risk and/or cardiovascular events will be
reviewed under these respective definitions.
Primary prevention
Studies have documented the value of statin drugs for
primary preventive care to lower cardiovascular risk. The West
of Scotland Coronary Prevention Study (WOSCOPS),
considered the pioneer study, was a randomized double blind
primary prevention study that showed that the administration
of pravastatin in 6595 men aged 45 to 64 years with
cholesterol levels greater than 6.23 mmol/L significantly
reduced cardiovascular mortality and morbidity in the
treatment group during a follow up period of almost 5 years
(Shepherd et al 1995a). A similar study, the Air Force/Texas
Coronary Atherosclerosis Prevention trial (AFCAPS/
TexCAPS), included both men and women with elevated
cholesterol levels and utilized another statin drug, lovastatin
(Downs et al 1998). This study found similar results, a
significant reduction in cardiovascular mortality and
morbidity in the treatment group.
Recently an attempt has been made to address the
management of an individual with multiple cardiovascular
risk factors and a cholesterol level below what is currently
considered to be an indication for statin therapy. The lipid arm
of the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid
Lowering Arm (ASCOT-LLA) trial has followed 10 305
individuals with hypertension and three other cardiovascular
risk factors, but not a prior acute cardiac event, and total
cholesterol levels of less than 6.49 mmol/L, randomized to
atorvastatin 10 mg or a placebo (Sever et al 2003). In a
prematurely terminated follow up period of 3.3 years,
individuals randomized to the treatment group had a
significantly lower incidence of acute cardiac events.
These data on individuals at a high cardiovascular risk
with borderline cholesterol levels have been reinforced by
the Atorvastatin Cardiac Outcomes Trial (CARDS) (Colhoun
et al 2004). In this outcomes-based trial, 2838 type II diabetic
patients, none of who had suffered an acute cardiac event,
and all of who had LDL levels less than 4.16 mmol/L, were
randomized to atorvastatin 10 mg or a placebo. Again, in a
prematurely terminated follow up period of almost four years,
those randomized to the treatment group had a significantly
lower incidence of cardiovascular events. The subsequent
publication of the extension to the NCEP-ATPIII guidelines
which now confirms diabetes mellitus patients as individuals
at high cardiovascular risk and thus falling into a secondary
cardiovascular prevention category probably renders the
findings of CARDS as superfluous (Grundy et al 2004).
However, because it preceded the release of the extension to
the guidelines, it assists in their validation.
It is reasonable to conclude, as a result of these studies,
that individuals should be routinely surveyed for an elevated
cholesterol level, particularly if other cardiovascular risk
factors are present, and if found such patients should be
commenced on a statin drug. Furthermore, individuals with
several cardiovascular risk factors and a normal or minimally
elevated cholesterol level should also be commenced on
statin therapy, a concept reinforced by recently published
trials data. The numbers of individuals or patients now being
considered for statin therapy for primary cardiovascular
prevention are gradually increasing with an increasing
understanding of the individuals’ cardiovascular risk and
how this risk may be reduced.
Secondary Prevention
There are numerous outcomes based clinical studies that have
confirmed the value of secondary prevention using statins
in patients with documented coronary artery disease or who
have suffered an acute cardiovascular event (Four S Group
1994; Sacks et al 1996; HPS Group 2002; Pitt et al 1999;
Reigger et al 1999; Farnier et al 2000; Schwartz et al 2001;
Athyros et al 2002). The Scandinavian Simvastatin Survival
Study (4S) randomized 4444 patients with elevated
cholesterol levels to the statin drug simvastatin, average dose
26 mg (qd), or a placebo, and documented the prognostic
benefits of the statin drug in the treatment group (Four S
Group 1994). The Cholesterol and Recurrent Events Trial
(CARE) showed similar results in 4159 patients with normal
cholesterol levels at the time of entry to the study, utilizing
pravastatin 40 mg (qd) in the treatment arm of the study
(Sacks et al 1996). Confirmation of the concept of treating a
patient with coronary disease and normal cholesterol with a
preventative statin drug has been provided by the recently
published Heart Protection Study (HPS), which randomized
20 536 patients with normal cholesterol levels, the majority
of which fell into the secondary prevention category, and
utilized simvastatin 40 mg (qd) in the treatment arm of the
study, with identical results (HPS Group 2002).
Several other trials, utilizing maximal available or
appropriate doses of atorvastatin and fluvastatin, have providedVascular Health and Risk Management 2006:2(4) 443
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similar conclusions regarding the reduction in cardiovascular
risk, confirming the concept that the capability of these statin
drugs to reduce cardiovascular mortality and the incidence of
cardiac events appeared to be a class effect of these medications
(Pitt et al 1999; Reigger et al 1999; Farnier et al 2000; Schwartz
et al 2001; Athyros et al 2002). Furthermore, the Myocardial
Ischemia Reduction with Aggressive Cholesterol Lowering
study (MIRACL) showed clearly that these medications may
be commenced promptly following the patient’s acute cardiac
event (Schwartz et al 2001). In the MIRACL study, 3086
patients admitted with an acute cardiac event were randomized
within 24 to 96 hours of their event, to atorvastatin 80 mg (qd)
or a placebo for 16 weeks. The composite endpoint of mortality,
nonfatal myocardial infarction and unstable angina was
significantly lower in the treatment group.
All the trials addressing the issue of secondary prevention
of cardiovascular mortality and morbidity using statin therapy
indicate that standard management of cardiovascular risk in
a patient with coronary artery disease or one who has suffered
an acute cardiac event incorporates the use of a statin drug as
an integral part of their continuing care, irrespective of the
cholesterol level of the individual patient (Grundy 1998;
Gould et al 1998). Most recently the issues of dose and even
selection of statin drug have been raised by the outcomes
based studies addressing differing statin drugs at varying
doses or equivalent doses that have been recently published.
These issues are addressed subsequently in this review.
Guidelines for management, choices
of statins, and doses of statins
Guidelines have been provided by expert peers for the lipid
management of the cardiovascular patient. The report of the
National Cholesterol Education Program Expert Panel
provided these guidelines (NCEP Expert Panel 2001).
Furthermore, these guidelines have recently been extended
and clarified to include the diabetic patient and the elderly
patient, as well as lowering the targets for low-density
lipoprotein (LDL) for high risk and very high risk patients
(Grundy et al 2004). The revisions of the guidelines have
encouraged the use of methods of general cardiovascular risk
factor scoring, in particular to identify the individual with
multiple cardiovascular risk factors who still falls into the
category of primary prevention. Such an evaluation includes
screening for obesity, lack of exercise, cigarette smoking,
hypertension, and diabetes mellitus.
It is also clear that all the currently available statin drugs are
not capable of achieving the LDL targets provided in the NCEP
guidelines. Several studies have addressed this issue. The
CURVES trial has addressed the issue of the capability of five of
the currently available statins to lower LDL levels, showing that
atorvastatin has the greatest capability followed by simvastatin
(Jones et al 1998). The STELLAR trial showed similar capabilities
when comparing LDL lowering with rosuvastatin, atorvastatin,
simvastatin, and pravastatin (Jones et al 2003).
Until recently, secondary preventive management
utilizing a statin required merely the selection of the drug
and ensuring that the patient would take the drug for the rest
of their life. In patients at very high risk, it is now
recommended that the dose of the selected statin be titrated
to an LDL level of less than 70 mg/dL (Grundy et al 2004).
The retrospective analysis of the HPS patients with LDL levels
of less than 2.6 mmol/L showed that patients randomized to
the treatment group had improved outcomes compared to
those randomized to the placebo group (HPS Group 2002).
Aggressively titrating patients appeared to improve
outcomes. This concept of higher doses of more efficacious
statins providing incrementally increased benefit is illustrated
by the Pravastatin or Atorvastatin Evaluation and Infection
Therapy––Thrombolysis in Myocardial Infarction 22
(PROVE IT- TIMI 22) (Cannon et al 2004). The trial involved
4162 patients hospitalized for an acute coronary syndrome
randomized to pravastatin 40 mg or atorvastatin 80 mg and
followed for cardiovascular outcomes for a mean of 24 months.
The study showed that the more efficacious dose of
atorvastatin was associated with a greater reduction in
cardiovascular events than the less effective dose of
pravastatin. The subsequent extension to the guidelines for
the secondary prevention of cardiovascular risk consolidated
the recommendation that the aggressive lowering of LDL
levels by higher doses of the more efficacious statin drugs
provides incrementally increased prognostic benefit to the
patient. This has been further fortified by the publication of
the REVERSAL study, where patients placed on the more
efficacious dose of atorvastatin 80 mg arrested the
progression of ultrasonically documented coronary artery
disease compared with those placed on the less effective dose
of pravastatin 40 mg, where the disease was shown to continue
to progress (Nissen et al 2004a). These findings have been
recently reaffirmed in the ASTEROID trial with similar
ultrasonic parameters utilizing rosuvastatin (Nissen 2006).
The concept of class effect of statins regarding the
secondary preventive management of cardiovascular risk has
existed for several years and has been supported by multiple
outcomes based secondary prevention trials providing similarVascular Health and Risk Management 2006:2(4) 444
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results utilizing all the available statin drugs except
rosuvastatin (Nixon 2004). These patients clearly appear to
benefit from early commencement of therapy as well as the
incremental titration of the dose of the statin drug to the
highest necessary or the highest tolerated dose determined
by the level of LDL. Recent outcomes based trials have
suggested that some statins may provide even greater benefit
by the utilization of their pleotropic effects. This issue has
come under consideration with the recent publication of phase
Z of the A to Z trial (de Lemos et al 2004). This study of 4497
acute coronary syndrome patients randomized to simvastatin,
first 40 mg and then 80 mg, or to a control group initially
given a placebo and subsequently simvastatin 20 mg, had
patients followed for cardiovascular outcomes for up to 24
months. The study showed trends but no significant
differences in outcomes between the two groups, a different
finding compared with the PROVE IT study (Cannon et al
2004). It has been suggested that the substantial differences
in C reactive protein levels between the two treatment groups
in these studies may be an explanation for the variant
findings (Nissen 2004b). The respective C reactive protein
differentials were 38% in the PROVE IT trial and 17% in the
A to Z trial (Cannon et al 2004; de Lemos et al 2004). While
these differences may suggest that the varying pleotropic
effects of different stains may, in addition to their LDL
lowering capability, influence the individual statin drug’s
capacity for lowering cardiovascular risk in patients requiring
secondary preventive management, this issue at present
remains unresolved until further studies elucidating these
differences are completed.
Preventive management
in the elderly
For several years questions have been asked as to whether there
should be an upper age limit for preventative management of
cardiovascular disease, in particular regarding the use of statin
therapy in an older age population (Grundy et al 1999). Mortality
and morbidity of cardiovascular disease is more prevalent over
65 years in a numerically growing population, accounting for
35% of all deaths in this age group, at substantial financial cost.
These questions are fortified by the fact that many outcomes
based clinical trials have upper age cut-offs of 65–70 years.
Among the primary prevention data using statin drugs,
WOSCOPS had an upper age cut-off of 65 years (Shepherd et al
1995a). In the AFCAPS/TexCAPS study, approximately one
quarter of the randomized subjects were over 65 years (Whitney
et al 1998). No significant differences in endpoints were found
when these subjects were analyzed separately.
Several observational studies have addressed the
association between age, cholesterol levels and mortality
in an older population. The Framingham Study, the
Epidemiological Study of the Elderly and the Honolulu
Heart program have shown that, in the average population
over the age of 70 years, there appears to be no statistical
relationship between age, cholesterol, and mortality
(Kronmal et al 1993; Krumholz et al 1994; Schatz et al
2001). Furthermore, a recent review of individuals 85 years
and older showed increased cholesterol levels were
associated with longevity, and adjustments for age, gender,
and cardiovascular risk factors failed to influence these
findings (Weverling-Rijnsburger 1997).
Secondary prevention of cardiovascular mortality and
morbidity using statin drugs in this age population, however,
has been addressed in several of the outcomes based trials. In
the 4S, CARE and the Heart Protection Study, the significant
differences in the trial between the treatment and the placebo
groups persisted in the older populations in the studies
(Miettinen et al 1997; Lewis et al 1998; HPS Group 2002).
The Prospective Study of Pravastatin in the Elderly at Risk
trial (PROSPER), an outcomes based prospective study of
5804 individuals aged 70–82 years randomized to pravastatin
or a placebo, showed a significant reduction in the secondary
endpoints of coronary heart disease death or nonfatal
myocardial infarction but not fatal and non-fatal stroke in
the treatment group compared with the placebo group after
an average follow up of 3.2 years (Shepherd et al 2002).
It is reasonable to conclude that over the age of 70 years,
statin drug utilization for the reduction of cardiovascular
mortality and morbidity risk should be confined to the patient
population who have a diagnosis of coronary disease or who
have had an acute cardiac event, which is as secondary
preventative therapy. Primary preventative therapy with
statins does not appear to be indicated in this age group.
These recommendations are now part of the extension to the
guidelines that were published recently (Grundy et al 2004).
Statins: properties and adverse
effects
Statin drugs are efficacious and safe, as has been confirmed
by the very low incidence of adverse effects in the many
large clinical trials already completed. Older individuals are
more likely to have side-effects of all therapies, including
statins (Gaist et al 2001). Adverse effects do not appear to be
dose related in all statins. They do, however, appear more
frequently in association with combination therapy, including
with niacin and fibrates (Shepherd et al 1995b). Because mostVascular Health and Risk Management 2006:2(4) 445
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statins utilize the cytochrome P450 3A4 metabolic pathway,
drugs inhibiting this pathway may potentially increase the
incidence of the adverse effects of the statins (Gruer et al
1999). This may apply particularly to other cardiovascular
drugs the patient may be taking. The most common complaints
are non-specific muscular aches and pains, without associated
muscle or hepatic enzyme changes, occurring in 3%–8% of
patients. Elevated hepatic enzymes occur in 0.5% to 1.0% of
patients. Rhabdomyolysis is rare (less than 1 death per million
patients). Attention has been drawn to the increased risk of
adverse effects with higher doses of simvastatin particularly
when used in combination therapy with niacin or fibrates, and
when given with verapamil and/or amiodarone (Gruer et al
1999).
It is clear that the statins have multiple properties, so called
pleiotropic properties, some of which are intriguing and will
require further elucidation. It is well established that these
medications alter the lipid profile in specific ways. Furthermore,
there is evidence that the drugs improve endothelial
dysfunction and lower inflammatory markers, including C-
reactive protein (Rader 2000). There are observational data to
suggest that these medications may prevent the onset of type
II diabetes mellitus, osteoporosis, atherosclerotic aortic valve
disease, ventricular arrhythmias, colon cancer, and senile
dementia (Freeman et al 2001; Raja and Dreyfus 2004). Clearly,
further outcomes based prospective studies are required to
confirm these observations.
Summary
The concept of the control of cholesterol levels in clinical
practice is now well established. Guidelines, recently extended,
are now provided to assist in management. The use of statin
drugs as an integral part of multifactorial management as primary
and secondary preventative therapy utilized to lower
cardiovascular mortality and morbidity risk is clearly indicated.
The patient population requiring primary preventive care using
statins continues to be extended. Patients requiring secondary
preventive care using statins are now clearly identified, as is
the recommendation of secondary preventive care for the
remainder of a patient’s life. Aggressive titration of statin drugs
to lower LDL levels for secondary prevention is also now
recommended. Recent data suggesting preferential statins will
require further elucidation.
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